Effect of empagliflozin on acute changes in eGFR and albuminuria
Between randomization and the 2 month follow-up visit, the
placebo-adjusted ‘acute dip’ in eGFR with empagliflozin was 2.12
(95% CI 1.83–2.41) mL/min/1.73mThe geometric mean study average uACR was 202 mg/g in the empagliflozin
group and 250 mg/g in the placebo group, a relative reduction in the
empagliflozin group of 19% (95% CI 15–23%). The relative reduction in
study average uACR varied substantially between different types of patient, in
particular by baseline uACR (